<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03706300</url>
  </required_header>
  <id_info>
    <org_study_id>641-14</org_study_id>
    <nct_id>NCT03706300</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Guaifenesin and Pseudoephedrine Hydrochloride Extended Release Tablets 1200/120 mg Under Fasting Conditions</brief_title>
  <official_title>An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single Dose, Crossover, Oral Bioequivalence Study of Guaifenesin and Pseudoephedrine Hydrochloride Extended Release Tablets 1200/120 mg of Dr. Reddy's Laboratories Ltd., India Comparing With Mucinex D (Guaifenesin and Pseudoephedrine Hydrochloride) Extended-release Bi-layer Tablets 1200/120 mg of Reckitt Benckiser Inc., USA in Healthy, Adult, Human Subjects Under Fasting Conditions.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label, balanced, randomized, two-treatment, two-period, two-sequence, single
      dose, crossover, oral bioequivalence study in healthy, adult, human subjects under fasting
      conditions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An open label, balanced, randomized, two-treatment, two-period, two-sequence, single dose,
      crossover, oral bioequivalence study of Guaifenesin and Pseudoephedrine Hydrochloride
      Extended Release Tablets 1200/120 mg of Dr. Reddy's Laboratories Ltd., India comparing with
      Mucinex D (Guaifenesin and Pseudoephedrine Hydrochloride) extended-release bi-layer tablets
      1200/120 mg of Reckitt Benckiser Inc., USA in healthy, adult, human subjects under fasting
      conditions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2014</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under curve</measure>
    <time_frame>Pre-dose (0.00), 0.25, 0.50, 0.75, 1.00, 1.25, 1.50, 1.75, 2.00, 2.50, 3.00, 3.50, 4.00, 4.50, 5.00, 5.50, 6.00, 7.00, 8.00, 10.00, 12.00, 14.00, 16.00, 20.00, 24.00, 36.00 and 48.00 hours post dose.</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Guaifenesin and Pseudoephedrine Hydrochloride ER Tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Guaifenesin and Pseudoephedrine Hydrochloride ER Tablets 1200/120 mg of Dr. Reddy's Laboratories Limited</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mucinex D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mucinex D extended-release bi-layer tablets 1200/120 mg of Reckitt Benckiser Inc., USA</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Guaifenesin and Pseudoephedrine Hydrochloride Extended Release Tablets 1200/120 mg</intervention_name>
    <arm_group_label>Guaifenesin and Pseudoephedrine Hydrochloride ER Tablets</arm_group_label>
    <arm_group_label>Mucinex D</arm_group_label>
    <other_name>Mucinex D</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        i. Volunteers who provide written informed consent.

        ii. Must be healthy, adult, humans between 18 and 45 years of age (both inclusive) weighing
        at least 55 kg.

        iii. Having a body mass index between 18.5 and 24.9 (both inclusive), calculated as weight
        in Kg/height in m2.

        iv. Must be of normal health as determined by medical history, physical examination and
        laboratory investigation performed within 28 days prior to the commencement of the study.
        (Laboratory values must be within normal limits or considered by the physician /
        investigator to be of no clinical significance).

        v. Female Subjects

          1. of child bearing potential practicing an acceptable method of birth control for the
             duration of the study as judged by the investigator(s), such as condoms, foams,
             jellies, diaphragm, intrauterine device, or abstinence.

          2. surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy
             has been performed on the subject)

        Exclusion Criteria:

        i. Incapable of understanding the informed consent.

        ii. Systolic blood pressure less than 90 mm of Hg or more than 140 mm of Hg.

        iii. Diastolic blood pressure less than 60 mm of Hg or more than 90 mm of Hg.

        iv. Oral temperature is below 95.0°F or above 98.6°F.

        v. Pulse rate below 60/min or above 100/min.

        vi. History of hypersensitivity or idiosyncratic reaction to investigational drug product
        or any other related drugs.

        vii. Any evidence of impairment of renal, hepatic, cardiac, lung or gastrointestinal
        function.

        viii. Any evidence of hematological, immunological, endocrinological, dermatological,
        neurological, musculoskeletal and psychiatric conditions.

        ix. Consumption of grapefruit for the past ten days prior to the check-in, in each period.

        x. Regular smoker who has a habit of smoking more than nine cigarettes per day and has
        difficulty in abstaining from smoking during sample collection period.

        xi. Habit of alcoholism and difficulty in abstaining from alcohol 24 hours before the drug
        administration and throughout the sample collection period.

        xii. Difficulty in abstaining from xanthine containing food or beverages (like tea, coffee,
        chocolates and cola drinks) 24 hours before the drug administration and throughout the
        sample collection period.

        xiii. Intake of over the counter (OTC) or prescribed medications and enzyme modifying
        medication or systemic medication for the last 30 days before dosing and until last blood
        sample of the study.

        xiv. Difficulty in swallowing tablets.

        xv. Confirmed positive in alcohol screening.

        xvi. Confirmed positive in selected drug of abuse.

        xvii. Participated in any other clinical investigation using experimental drug/donated
        blood in past 90 days before the date of start of study.

        xviii. Female confirmed positive in urine pregnancy test.

        xix. Female detected to be pregnant, breast feeding or who is likely to become pregnant
        during the study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. K. Krishna Moorthy, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>QPS Bioserve India Pvt. Limited</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>QPS Bioserve India Pvt. Limited</name>
      <address>
        <city>Hyderabad</city>
        <state>Telangana</state>
        <zip>500 037</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>October 11, 2018</study_first_submitted>
  <study_first_submitted_qc>October 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 15, 2018</study_first_posted>
  <last_update_submitted>October 11, 2018</last_update_submitted>
  <last_update_submitted_qc>October 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phenylpropanolamine</mesh_term>
    <mesh_term>Pseudoephedrine</mesh_term>
    <mesh_term>Ephedrine</mesh_term>
    <mesh_term>Guaifenesin</mesh_term>
    <mesh_term>Chlorpheniramine, phenylpropanolamine drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

